PF-06647263

PF-06647263 is an ADC targeting EFNA4, consisting of EFNA4 Antibody (HY-P991109), ADC toxin Calicheamicin (HY-19609) and a linker. PF-06647263 exhibits anti-tumor activity and induces significant tumor regression in TNBC xenografts[1][2].

Product Specifications

CAS Number

[1822383-65-2]

Product Name Alternative

Anti-EFNA4-ADC

UNSPSC

12352211

Target

Antibiotic; Antibody-Drug Conjugates (ADCs) ; Apoptosis; DNA Alkylator/Crosslinker

Type

Reference compound

Related Pathways

Antibody-drug Conjugate/ADC Related; Anti-infection; Apoptosis; Cell Cycle/DNA Damage

Applications

COVID-19-immunoregulation

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/pf-06647263.html

Smiles

[PF-06647263]

References & Citations

[1]Garrido-Laguna I, et al. First-in-human, phase I study of PF-06647263, an anti-EFNA4 calicheamicin antibody-drug conjugate, in patients with advanced solid tumors. Int J Cancer. 2019 Oct 1;145 (7) :1798-1808. |[2]Damelin M, et al. Anti-EFNA4 Calicheamicin Conjugates Effectively Target Triple-Negative Breast and Ovarian Tumor-Initiating Cells to Result in Sustained Tumor Regressions. Clin Cancer Res. 2015 Sep 15;21 (18) :4165-73.